Bridgeway Capital Management Inc. increased its holdings in Insys Therapeutics Inc (NASDAQ:INSY) by 11.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 84,700 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,500 shares during the quarter. Bridgeway Capital Management Inc. owned approximately 0.11% of Insys Therapeutics worth $854,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in INSY. Tower Research Capital LLC TRC acquired a new stake in Insys Therapeutics during the second quarter valued at approximately $131,000. Creative Planning bought a new position in shares of Insys Therapeutics during the third quarter valued at approximately $153,000. BNP Paribas Arbitrage SA grew its holdings in shares of Insys Therapeutics by 47.4% during the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock valued at $225,000 after purchasing an additional 10,001 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Insys Therapeutics by 35.3% during the third quarter. Wells Fargo & Company MN now owns 77,101 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 20,100 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Insys Therapeutics by 33.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 126,335 shares of the specialty pharmaceutical company’s stock valued at $915,000 after purchasing an additional 31,840 shares during the last quarter. Institutional investors and hedge funds own 17.22% of the company’s stock.
Several equities analysts have recently commented on the company. ValuEngine raised Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. Zacks Investment Research lowered Insys Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Insys Therapeutics in a report on Friday, August 10th. Finally, Piper Jaffray Companies set a $4.00 target price on Insys Therapeutics and gave the company a “sell” rating in a report on Saturday, August 11th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $7.67.
NASDAQ:INSY opened at $5.18 on Friday. The company has a market cap of $395.11 million, a PE ratio of -10.57 and a beta of 1.58. Insys Therapeutics Inc has a 52 week low of $4.97 and a 52 week high of $14.00.
Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.08). Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 266.60%. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $24.05 million. During the same period last year, the company posted ($2.30) earnings per share. The firm’s revenue for the quarter was down 40.4% compared to the same quarter last year. On average, sell-side analysts predict that Insys Therapeutics Inc will post -1.32 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insys Therapeutics Inc (INSY) Position Lifted by Bridgeway Capital Management Inc.” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/08/insys-therapeutics-inc-insy-position-lifted-by-bridgeway-capital-management-inc.html.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Read More: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics Inc (NASDAQ:INSY).
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.